Browse through our ongoing projects, clinical trials, and research publications to learn about recent advancements in SLE research.

A central resource that collects, stores, and manages biological samples to support cutting-edge research on autoimmune diseases.
Focused on identifying new biomarkers to enable earlier and more accurate diagnosis of autoimmune diseases.
Dedicated to making research findings accessible, bridging the gap between scientific discoveries and practical, patient-centered information.
Harnesses AI and data science to develop predictive models that improve diagnosis, treatment, and personalized care in autoimmune research.
Aims to tailor treatments to individuals based on unique genetic and molecular profiles, enhancing the effectiveness of therapies.
Conducts rigorous trials to evaluate new treatments, ensuring safe and effective options for patients with autoimmune conditions.

Current Research Projects

CLIMB

Autoantibodies are proteins that mistakenly attack the body’s own tissues and can interact with other proteins in people with autoimmune inflammatory myopathies (AIM). We explore specific blood protein combinations that could lead to a test guiding treatment decisions and improving outcomes for those affected by AIM. Funded by Arthritis Society.

GAPS

We will examine the level of lupus awareness across the country using GoogleTrends. Supported by Lupus Canada.

ANA Reader©

Anti-nuclear antibody (ANA) is a blood test to diagnose many autoimmune disorders. We developed a machine-learning algorithm that can predict ANA patterns, speeding up the rate at which these tests are performed and increasing their accuracy. Funded by the McCaig Institute SPARC grant.

SPIN

Sporadic inclusion body myositis (sIBM) is a rare muscle disease that is often challenging to diagnose. We discovered several novel sIBM biomarkers involved in the immune, inflammatory, and degenerative pathways that may aid in the early diagnosis and our understanding of disease pathogenesis. Funded by the McCaig Institute SPARC grant.

RAAISE

Increase access to autoimmune diagnostic testing in remote communities including Africa and Indigenous communities. Funded by the University of Calgary Department of Medicine Clinical Research Fund and Astrazeneca.

Lupus Calculator

Patients diagnosed with systemic lupus erythematosus (SLE) have been shown to have an increased risk of developing cardiovascular events (CVDs), such as strokes and heart attacks. We created a calculator that can predict the risk of CVDs in SLE patients, using both traditional biomarkers of CVD, as well as SLE biomarkers. Funded by CIHR

Ongoing Clinical Trials

DAISY

Determine Effectiveness of Anifrolumab In SYstemic Sclerosis.

The purpose of this study is to evaluate the efficacy and safety of treatment with subcutaneous anifrolumab versus placebo in adult participants with systemic sclerosis. The target population for this study includes patients who meet the 2013 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) classification for systemic sclerosis, either limited or diffuse cutaneous subsets, with a disease duration of less than 6 years from first non-Raynaud's phenomenon symptom.

Trial number: NCT05925803

Visit Website

Contact Organizer

JASMINE

Anifrolumab SC in Patients With Idiopathic Inflammatory Myopathies (Polymyositis or Dermatomyositis)

The purpose of this multicenter, randomized, placebo-controlled and double-blind study is to evaluate the efficacy and safety of subcutaneous anifrolumab compared with placebo on the overall disease activity in participants with moderate to severe Idiopathic Inflammatory Myopathies (IIM) [polymyositis (PM) or dermatomyositis (DM)] while receiving standard of care (SoC) treatment.

Trial number: NCT06455449

Visit Website

Contact Organizer